Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 in PD-L1 Positive Recurrent or Metastatic Cervical Cancer
NCT04623333Phase 2Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Nov 2020
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of benmelstobart in Cervical Cancer (CC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Overall Response Rate evaluated by Independent Review Committee up to 12 months. Status: unknown.
02
Drugs
benmelstobart
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04623333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04623333.